Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLASE, INCBIOL · Entity 11470 | Director | June 08, 2023 | June 12, 2023 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLASE, INC
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 554,596 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 512,821 · Balance 554,596 F1: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F2: The restricted stock unit award fully vests and is immediately exercisable upon the eleventh month anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent.
F2: The restricted stock unit award fully vests and is immediately exercisable upon the eleventh month anniversary of the date of grant.
REVELATION BIOSCIENCES, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,839 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 32,011 · Balance 44,839 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DEXCOM INC
Report date April 01, 2017 · Filed April 20, 2017
Section 16 reporting ended · disclosed 2017-04-20. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 32,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355659 · ownership.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,839 F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:31 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | Tax withholdingCommon Stock | 1,591 | $1.85 | $2,943.35 |
DisclosureSEC source: 0001193125-26-039700 · ownership.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,828 F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:08 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 41,981 | $0.90 | $37,782.90 |
DisclosureSEC source: 0001193125-26-010613 · ownership.xml · nonDerivative · entry 2 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,667 F1 · security: Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 16:54 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 15,625 | $1.28 | $20,000.00 |
DisclosureSEC source: 0001193125-25-260415 · ownership.xml · nonDerivative · entry 2 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,686 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 23:09 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 181 | $3.87 | $700.47 |
DisclosureSEC source: 0000950170-25-020113 · ownership.xml · nonDerivative · entry 2 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 09:07 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 512,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036154 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 554,596 Underlying: Common Stock · 512,821 shares Expires not disclosed F1 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable upon the eleventh month anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable upon the eleventh month anniversary of the date of grant. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 20:07 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantStock Option (Right to Buy) · Derivative | 6,356 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-23-024643 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,356 Underlying: Common Stock · 6,356 shares Expires 2033-04-14 F1 · derivative.exercise_date: The stock options vest and become exercisable on the grant date. Read SEC document |
| May 11, 2022 Filed May 13, 2022 10:34 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 41,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028766 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,775 Underlying: Common Stock · 41,775 shares Expires not disclosed F1 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable upon the one year anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable upon the one year anniversary of the date of grant. Read SEC document |
| April 28, 2022 Filed May 2, 2022 13:45 UTC | BIOLASE, INC BIOL · Entity 11470 | Disposition to issuerSeries G Preferred Stock | 345.863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-016097 · doc4.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On March 1, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series G Preferred Stock, par value $0.001 per share ("Preferred Stock"), for each outstanding share of Company Common Stock to stockholders of record at 5:00 p.m. Eastern Time on March 25, 2022 (the "Record Date"), in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on March 25, 2022. As a result, the Reporting Person received 345.863 shares of Preferred Stock. The Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On April 28, 2022, these shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation for the shares of Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each ten whole shares of Preferred Stock, with any remaining shares (of less than 10) receiving no cash. F2 · price: On April 28, 2022, these shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation for the shares of Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each ten whole shares of Preferred Stock, with any remaining shares (of less than 10) receiving no cash. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 20:55 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 138,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040458 · doc4.xml · derivative · entry 2 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,000 Underlying: Common Stock · 138,000 shares Expires not disclosed F2 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F3 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023, F3 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023, Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 20:55 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantStock Appreciation Right · Derivative | 111,337 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-040458 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,337 Underlying: Common Stock · 111,337 shares Expires 2031-06-11 F1 · derivative.exercise_date: Of the stock appreciation rights subject to this SAR, one-fourth of the stock appreciation rights vest on each of the third, sixth, ninth, and twelfth-month anniversaries of the date of grant. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 09:46 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-045866 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,397 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. Read SEC document |
| May 13, 2020 Filed May 28, 2020 12:02 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantStock Option (right to buy) · Derivative | 187,378 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-20-032536 · doc4.xml · derivative · entry 2 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,378 Underlying: Common Stock · 187,378 shares Expires 2030-05-13 F3 · derivative.exercise_date: The stock option vests and is immediately exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service. Read SEC document |
| May 13, 2020 Filed May 28, 2020 12:02 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 165,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032536 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,397 Underlying: Common Stock · 165,245 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 10:57 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 75,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-045265 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,485 Underlying: Common Stock · 75,152 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the nine month anniversary of the date of the award. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the nine month anniversary of the date of the award. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 11:02 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038458 · doc4.xml · derivative · entry 1 ROPER JESS · CIK 0001408993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests on May 9, 2019. F2 · derivative.expiration_date: The restricted stock unit award fully vests on May 9, 2019. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,000 | $75.97 | $151,936.60 |
DisclosureSEC source: 0001093557-17-000093 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,452 F1 · shares: On November 04, 2016, Mr. Roper adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Roper. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.19 to $76.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the LJR Family Trust U/T/A DTD 08/08/2013, with respect to which the reporting person is a trustee. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 23:58 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 5,120 | $77.55 | $397,059.07 |
DisclosureSEC source: 0001093557-17-000075 · edgardoc.xml · nonDerivative · entry 3 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,497 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 33,333 unvested restricted stock units, 20,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 23:58 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,948 | $77.55 | $151,068.57 |
DisclosureSEC source: 0001093557-17-000075 · edgardoc.xml · nonDerivative · entry 2 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,617 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 33,333 unvested restricted stock units, 20,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 23:58 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,538 | $77.55 | $196,823.42 |
DisclosureSEC source: 0001093557-17-000075 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,565 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 33,333 unvested restricted stock units, 20,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:51 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,333 | $78.76 | $183,758.51 |
DisclosureSEC source: 0001093557-17-000036 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,452 F1 · shares: On November 04, 2016, Mr. Roper adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Roper. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $78.23 to $79.75. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the LJR Family Trust U/T/A DTD 08/08/2013, with respect to which the reporting person is a trustee. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 23:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,012 | $85.01 | $256,050.72 |
DisclosureSEC source: 0001093557-17-000017 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,785 F1 · shares: On November 04, 2016, Mr. Roper adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Roper. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 84.39 to 85.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the LJR Family Trust U/T/A DTD 08/08/2013, with respect to which the reporting person is a trustee. Read SEC document |
| December 14, 2016 Filed Dec 17, 2016 00:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,442 | $64.14 | $156,619.38 |
DisclosureSEC source: 0001093557-16-000762 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,797 F1 · shares: On November 04, 2016, Mr. Roper adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Roper. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.68 to $64.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the LJR Family Trust U/T/A DTD 08/08/2013, with respect to which the reporting person is a trustee. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,471 | $80.75 | $199,544.37 |
DisclosureSEC source: 0001093557-16-000733 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,215 F1 · shares: On November 20, 2015, Mr. Roper adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Roper. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.39 to $80.98. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 55,000 unvested restricted stock units, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 20,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 5,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 23:52 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,470 | $93.99 | $232,155.30 |
DisclosureSEC source: 0001093557-16-000711 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,686 F1 · shares: On November 20, 2015, Mr. Roper adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Roper. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $93.81 to $94.23. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 55,000 unvested restricted stock units, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 20,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 5,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:31 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,556 | $93.72 | $333,277.57 |
DisclosureSEC source: 0001093557-16-000693 · edgardoc.xml · nonDerivative · entry 2 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,156 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 55,000 unvested restricted stock units, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 20,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 5,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:31 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,667 | $93.72 | $249,958.17 |
DisclosureSEC source: 0001093557-16-000693 · edgardoc.xml · nonDerivative · entry 1 ROPER JESS · CIK 0001408993 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,712 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 55,000 unvested restricted stock units, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 20,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 5,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.